Sphingosine-1-phosphate receptor-1 (S1P 1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease

Mucosal Immunology

Volumn 10, Issue 1, 2017, Pages 162-171

  Karuppuchamy, T ^a,b   Behrens, E H ^a,b   Gonzalez Cabrera P ^c   Sarkisyan, G ^c   Gima, L ^a,b   Boyer, J D ^a,b   Bamias, G ^d   Jedlicka, P ^e   Veny, M ^a,b   Clark, D ^a,b   Peach, R ^f   Scott, F ^f   Rosen, H ^c   Rivera Nieves, J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d LAIKO GENERAL HOSPITAL   (Greece)

^e UNIVERSITY OF COLORADO   (United States)

^f Receptos Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45RB ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; DEXTRAN SULFATE; IMMUNOLOGIC FACTOR; INDAN DERIVATIVE; OXADIAZOLE DERIVATIVE; OZANIMOD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; COLITIS; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; ENDOTHELIUM CELL; ILEITIS; INFLAMMATORY BOWEL DISEASE; LAMINA PROPRIA; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; DISEASE MODEL; ENDOTHELIUM; GENETICS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE; LYMPHOCYTE; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; COLITIS; DENDRITIC CELLS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENDOTHELIUM; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; INDANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXADIAZOLES; RECEPTORS, LYSOSPHINGOLIPID;

EID: 85011045343     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2016.35     Document Type: Article

References (42)

1. Feagan, B.G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699-710 (2013).
2. Sandborn, W.J. et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 369, 711-721 (2013).
3. Ghosh, S. et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
4. Sandborn, W. et al. The TOUCHSTONE study: a randomized, doubleblind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe ulcerative colitis. Gastroenterology 148: S93.
5. Zhang, H., Desai, N.N., Olivera, A., Seki, T., Brooker, G. &Spiegel, S. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J. Cell Biol. 114, 155-167 (1991).
6. Eigenbrod, S., Derwand, R., Jakl, V., Endres, S. &Eigler, A. Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells. Immunol. Invest. 35, 149-165 (2006).
7. Schwab, S.R., Pereira, J.P., Matloubian,M., Xu, Y.,Huang, Y.and Cyster, J.G. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309, 1735-1739 (2005).
8. Sanchez, T. &Hla, T. Structural and functional characteristics of S1P receptors. J. Cell. Biochem. 92, 913-922 (2004).
9. Collins, C.B. et al. CD44 deficiency attenuates chronic murine ileitis. Gastroenterology 135, 1993-2002 (2008).
10. Gaengel, K. et al. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev. Cell 23, 587-599 (2012).
11. Choi, J.W. et al. FTY720 (fingolimod) efficacy in an animal model ofmultiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. USA 108, 751-756 (2011).
12. Mandala, S. et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346-349 (2002).
13. Cinamon, G., Zachariah, M.A., Lam, O.M., Foss, F.W. Jr. &Cyster, J.G. Follicular shuttling of marginal zoneBcells facilitates antigen transport. Nat. Immunol. 9, 54-62 (2008).
14. Sanna, M.G. et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 279, 13839-13848 (2004).
15. Allende, M.L., Yamashita, T. &Proia, R.L. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102, 3665-3667 (2003).
16. Awad, A.S. et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. Renal Physiol. 290, F1516-F1524 (2006).
17. Cahalan, S.M. et al. Actions of a picomolar short-acting S1P(1) agonist in S1P(1)-eGFP knock-in mice. Nat. Chem. Biol. 7, 254-256 (2011).
18. Hart, A.L., Ng, S.C.,Mann, E., Al-Hassi, H.O., Bernardo, D. &Knight, S.C. Homing of immune cells: role in homeostasis and intestinal inflammation. Inflamm. Bowel Dis. 16, 1969-1977 (2010).
19. Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897 (2010).
20. Spiegel, S. and Milstien, S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 11, 403-415 (2011).
21. Skon, C.N., Lee, J.Y., Anderson, K.G., Masopust, D., Hogquist, K.A. &Jameson, S.C. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ Tcells. Nat. Immunol. 14, 1285-1293 (2013).
22. Czeloth, N., Bernhardt, G., Hofmann, F., Genth, H. &Forster, R. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J. Immunol. 175, 2960-2967 (2005).
23. Gollmann, G. et al. Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. Int. Immunol. 20, 911-923 (2008).
24. Maeda, Y., Matsuyuki, H., Shimano, K., Kataoka, H., Sugahara, K. &Chiba, K. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3 J. Immunol. 178, 3437-3446 (2007).
25. Lenschow, D.J. et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5, 285-293 (1996).
26. MacDonald, K.P., Munster, D.J., Clark, G.J., Dzionek, A., Schmitz, J. &Hart, D.N. Characterization of human blood dendritic cell subsets. Blood 100, 4512-4520 (2002).
27. Kontoyiannis, D., Pasparakis, M., Pizarro, T.T., Cominelli, F. &Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNFAU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387-398 (1999).
28. Collins, C.B. et al. Flt3 ligand expands CD103+ dendritic cells and FoxP3+ T regulatory cells, and attenuates Crohn's-like murine ileitis. Gut 61, 1154-1162 (2012).
29. Hatoum, O.A., Miura, H. &Binion, D.G. The vascular contribution in the pathogenesis of inflammatory bowel disease. Am. J. Physiol. Heart Circ. Physiol. 285, H1791-H1796 (2003).
30. Montrose, D.C. et al. S1P(1) localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J. Lipid Res. 54, 843-851 (2013).
31. Deguchi, Y. et al. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol. Rep. 16, 699-703 (2006).
32. Mizushima, T. et al. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm. Bowel Dis. 10, 182-192 (2004).
33. Fujii, R. et al. FTY720 suppresses CD4+CD44highCD62L-effector memory Tcell-mediated colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G267-G274 (2006).
34. Daniel, C., Sartory,N., Zahn, N.,Geisslinger, G.,Radeke, H.H. &Stein, J.M. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J. Immunol. 178, 2458-2468 (2007).
35. Radi, Z.A., Heuvelman, D.M., Masferrer, J.L. &Benson, E.L. Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBSinduced Crohn's disease model. Dig. Dis. Sci. 56, 2283-2291 (2011).
36. Liao, J.J. et al. Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor. FASEB J. 23, 1786-1796 (2009).
37. Song, J. et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J. Pharmacol. Exp. Ther. 324, 276-283 (2008).
38. McNamee, E.N., Masterson, J.C., Jedlicka, P., Collins, C.B.,Williams, I.R. &Rivera-Nieves, J. Ectopic lymphoid tissue alters the chemokine gradient, increases lymphocyte retention and exacerbates murine ileitis. Gut 62, 53-62 (2013).
39. McNamee, E.N. et al. Novel model of TH2-polarized chronic ileitis: The SAMP1 mouse. Inflamm. Bowel. Dis. 16, 743-752 (2010).
40. Burns, R.C., Rivera-Nieves, J., Moskaluk, C.A., Matsumoto, S., Cominelli, F. &Ley, K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 121, 1428-1436 (2001).
41. Sarkisyan, G., Cahalan, S.M., Gonzalez-Cabrera, P.J., Leaf, N.B. &Rosen, H. Real-time differential labeling of blood, interstitium, and lymphatic and single-field analysis of vasculature dynamics in vivo. Am. J. Physiol. Cell Physiol. 302, C1460-C1468 (2012).
42. Sarkisyan, G., Gay, L.J., Nguyen, N., Felding, B.H. &Rosen, H. Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth. Am. J. Physiol. Cell Physiol. 307, C14-C24 (2014).